1. Home
  2. SST vs INAB Comparison

SST vs INAB Comparison

Compare SST & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo System1 Inc.

SST

System1 Inc.

HOLD

Current Price

$3.05

Market Cap

12.9M

ML Signal

HOLD

Logo IN8bio Inc.

INAB

IN8bio Inc.

N/A

Current Price

$1.47

Market Cap

13.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SST
INAB
Founded
2013
2016
Country
United States
United States
Employees
250
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.9M
13.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
SST
INAB
Price
$3.05
$1.47
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$10.00
$6.00
AVG Volume (30 Days)
151.9K
60.7K
Earning Date
05-06-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.35
$1.17
52 Week High
$11.30
$2.73

Technical Indicators

Market Signals
Indicator
SST
INAB
Relative Strength Index (RSI) 49.89 40.72
Support Level $3.09 $1.35
Resistance Level $3.72 $1.85
Average True Range (ATR) 0.32 0.10
MACD 0.00 -0.02
Stochastic Oscillator 33.19 15.77

Price Performance

Historical Comparison
SST
INAB

About SST System1 Inc.

System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It operate several flagship brands across multiple consumer verticals, including shopping, travel and search, and a customer acquisition and marketing platform powered by Artificial Intelligence and machine learning. The company's segment includes Marketing and Products. It generates maximum revenue from the Marketing segment. Geographically, it operates in United States and Other countries.

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

Share on Social Networks: